Through this deal PCI targets European growth and mitigates against uncertainty brought about by Brexit
PCI Pharma Services has acquired pharmaceutical and healthcare contract packaging services provider Millmount Healthcare, located near Dublin, Ireland.
Millmount has been serving pharmaceutical and healthcare customers for more than 20 years with advanced capability in the areas of blister packaging, bottling and tub filling, as well as offering expertise in late-stage customisation and cold chain packaging services.
Additionally, Millmount has invested in expanding its potent compound packaging capability, recently opening a new high potent, high containment packaging facility.
“We are very excited to welcome the Millmount team to PCI,” said Bill Mitchell, President and CEO. “We continue to see strong demand from our customers for medicines targeted for international growth markets both in commercial medicines as well as investigational medicines for clinical trials.”
PCI currently supports medicines destined for more than 100 countries around the world. The acquisition of Millmount and presence in Ireland further underscores PCI’s strategy and commitment to be the partner of choice to meet the global market needs of its customers. The addition of Millmount will mark the company’s fourth acquisition outside of the US in four years.
“With Millmount’s geographic presence in the European Union, we also see tremendous value in helping mitigate any uncertainty brought about by the evolving Brexit situation. We see Millmount’s strengths and investments as complementary to PCI’s and this will further help us deliver the industry-leading experience to our clients as we partner in delivering life-saving medicines to patients around the world.”
Pascal Keogh, the founder of Millmount, said: “I am delighted Millmount is joining the PCI community and firmly believe this is a very positive event for our employees and customers. PCI is clearly a market-leading, global organisation that will allow Millmount to expand into new service lines, including serialisation, as well as accelerate growth of the business.”
With the addition of Millmount, PCI will now have 18 facilities across North America and Europe, employing over 3,200 people.
In addition to commercial packaging, Millmount is licensed to support clinical trial medicines, and PCI expects to immediately initiate site training and facility upgrades to support storage, distribution and QP release of clinical trial supplies. The aim is for the Millmount facilities to become an important hub for its Clinical Trial Services business given its strategic position in the European Union.
PCI, headquartered in Philadelphia, PA, is principally owned by Partners Group, with partner investors Thomas H. Lee Partners and Frazier Healthcare.